Physician profile
Ramy Ayad
NPI 1447245659
$3,394.23
in general payments reported to CMS, 2019-2025
23 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $77.96 · 2021: $183 · 2022: $396 · 2023: $644 · 2024: $813 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $799.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $493.58 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $414.31 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $379.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.76 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $242.32 | 2019-2025 | Farxiga |
| Philips North America LLC | $170.44 | 2024-2025 | (Ck4) Mcot, Extended Holter, (Ck7) Extended Holter |
| Amarin Pharma, INC. | $99.68 | 2019-2021 | |
| Innovation Technologies INC | $64.30 | 2022 | |
| Novo Nordisk INC | $63.72 | 2023-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $61.54 | 2023-2025 | Watchman Flx, Varithena Administration Pack |
| Amgen INC. | $41.48 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $40.50 | 2021-2023 | Arcalyst |
| Recor Medical INC | $38.80 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Esperion Therapeutics, INC. | $37.22 | 2024 | Nexletol |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $35.69 | 2023 | Flexitouch Plus, Entre Plus |
| Merck Sharp & Dohme LLC | $31.95 | 2022-2023 | Verquvo |
| Convatec INC. | $28.30 | 2023 | |
| Medtronic, INC. | $24.53 | 2025 | Symplicity G3 |
| Kiniksa Pharmaceuticals International, Plc | $19.51 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $16.50 | 2023 | |
| Cvrx, INC. | $16.17 | 2022 | |
| Heartflow, INC. | $14.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramy Ayad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.